This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DYAX Dyax (DYAX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Dyax Stock (NASDAQ:DYAX) 30 days 90 days 365 days Advanced Chart Get Dyax alerts:Sign Up Key Stats Today's Range$38.41▼$38.4150-Day Range N/A52-Week Range$14.06▼$38.56VolumeN/AAverage Volume5.25 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development. Read More Receive DYAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyax and its competitors with MarketBeat's FREE daily newsletter. Email Address DYAX Stock News HeadlinesAbbVie IncSeptember 18, 2024 | nytimes.comNanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and QualityMay 14, 2024 | finance.yahoo.com10 Cheap Stocks Ready to ExplodeRemember when Nvidia was trading at $60? Yeah, me too. Painful, right? While early investors turned every $10,000 into $100,000+, most of us watched from the sidelines, thinking we'd already missed the boat. Here's the thing though... The AI revolution isn't over. It's just getting started.July 25 at 2:00 AM | TradingTips (Ad)Anokion SA: Anokion Strengthens its Senior Leadership with Promotions and New AppointmentSeptember 7, 2023 | finanznachrichten.deAnokion Strengthens its Senior Leadership with Promotions and New AppointmentSeptember 7, 2023 | finance.yahoo.comMost immigrants in West Virginia are from these countriesJuly 17, 2023 | msn.comIs David Corenswet A Good Fit For Superman? Here's How /Film Readers FeelJuly 17, 2023 | msn.comMost immigrants in Virginia are from these countriesJuly 17, 2023 | msn.comSee More Headlines DYAX Stock Analysis - Frequently Asked Questions How were Dyax's earnings last quarter? Dyax Corp (NASDAQ:DYAX) posted its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The business's revenue was up 12.3% compared to the same quarter last year. What other stocks do shareholders of Dyax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyax investors own include (KRFT) (KRFT), Bristol Myers Squibb (BMY), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD) and Novavax (NVAX). Company Calendar Last Earnings10/28/2015Today7/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:DYAX CIK907562 Webwww.dyax.com Phone+1-617-2505769FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:DYAX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyax Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.